From our founding, we made the decision that we’d be different

In the way we’re structured, in the people we hire, in our trials and technology—and in the way we research and innovate the transformative solutions on the frontiers of oncology, autoimmune disease, and pain management.

Shifting toward disease-centric therapies, we seek to treat patients holistically, allowing us to target diseases and their consequences on the human body on multiple levels.

Shifting our approach to treating cancer
Research

Strategic priorities for biologics discovery research in immuno-oncology

FOCUS ON DISEASE CENTRIC APPROACH AND LEVERAGE BEAT® ANTIBODY ENGINEERING PLATFORM TO DELIVER FIRST IN CLASS CANDIDATES
MULTIPLE MYELOMA (MM)
Optimize molecular attributes of ISB 1342 (CD38xCD3)
T cell engager
Deliver a competitive MM portfolio by advancing next wave of T cell engagers and Innate immune engagers (e.g. NK, macrophages)
HEMATOLOGICAL MALIGNANCIES
Accelerate delivery of innovative concepts by leveraging Tri-specific T cell and Innate immune engagers (e.g. NK, macrophages)
SOLID TUMORS
Optimize molecular attributes of ISB 1302 (Her2xCD3) T cell engager
Accelerate delivery of new targets to address unmet medical needs in solid tumors

Shifting our approach to treating cancer

The current cancer treatment landscape is carved from centuries of scientific knowledge, gained by those dedicated to advancing a greater understanding of the human body. Diagnoses once thought incurable have now shifted, with new thinking, new research, new therapies, and new discoveries made possible by those who walked the path of innovation before us.1

Now, it’s our turn. We’re pioneering advancements in oncology that enhance the immune system’s ability to detect and kill cancer. Born from our patented BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform, our immuno-oncology assets currently in Phase 1 clinical trials facilitate binding of powerful immune cells called CD3 (or T cells) to HER2 and CD38 expressing tumors.2 This may allow for the treatment of cancers such as breast and multiple myeloma, including those non-responsive or resistant to standard of care.

We believe our path to innovation holds great promise for the future, to treat cancer differently.


Strategic priorities for biologics discovery research in immuno-oncology

FOCUS ON DISEASE CENTRIC APPROACH AND LEVERAGE BEAT® ANTIBODY ENGINEERING PLATFORM TO DELIVER FIRST IN CLASS CANDIDATES
MULTIPLE MYELOMA (MM)
Optimize molecular attributes of ISB 1342 (CD38xCD3)
T cell engager
Deliver a competitive MM portfolio by advancing next wave of T cell engagers and Innate immune engagers (e.g. NK, macrophages)
HEMATOLOGICAL MALIGNANCIES
Accelerate delivery of innovative concepts by leveraging Tri-specific T cell and Innate immune engagers (e.g. NK, macrophages)
SOLID TUMORS
Optimize molecular attributes of ISB 1302 (Her2xCD3) T cell engager
Accelerate delivery of new targets to address unmet medical needs in solid tumors
Research

Strategic priorities for biologics discovery research in immuno-oncology

FOCUS ON DISEASE CENTRIC APPROACH AND LEVERAGE BEAT® ANTIBODY ENGINEERING PLATFORM TO DELIVER FIRST IN CLASS CANDIDATES
MULTIPLE MYELOMA (MM)
Optimize molecular attributes of ISB 1342 (CD38xCD3)
T cell engager
Deliver a competitive MM portfolio by advancing next wave of T cell engagers and Innate immune engagers (e.g. NK, macrophages)
HEMATOLOGICAL MALIGNANCIES
Accelerate delivery of innovative concepts by leveraging Tri-specific T cell and Innate immune engagers (e.g. NK, macrophages)
SOLID TUMORS
Optimize molecular attributes of ISB 1302 (Her2xCD3) T cell engager
Accelerate delivery of new targets to address unmet medical needs in solid tumors

The current cancer treatment landscape is carved from centuries of scientific knowledge, gained by those dedicated to advancing a greater understanding of the human body. Diagnoses once thought incurable have now shifted, with new thinking, new research, new therapies, and new discoveries made possible by those who walked the path of innovation before us.1

Now, it’s our turn. We’re pioneering advancements in oncology that enhance the immune system’s ability to detect and kill cancer. Born from our patented BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform, our immuno-oncology assets currently in Phase 1 clinical trials facilitate binding of powerful immune cells called CD3 (or T cells) to HER2 and CD38 expressing tumors.2 This may allow for the treatment of cancers such as breast and multiple myeloma, including those non-responsive or resistant to standard of care.

We believe our path to innovation holds great promise for the future, to treat cancer differently.

Shifting novel autoimmune disease treatments forward
research

Shifting novel autoimmune disease treatments forward

At Ichnos Sciences, we’re working to change the therapeutic approaches of autoimmune diseases.

With a deep understanding of the body’s aberrant autoimmune response that leads to the immune system attacking healthy cells and causing inflammation, our molecule, ISB 830, is designed to block the key immune system activation factor, OX-40.3 By blocking OX-40 on the surface of T cells, ISB 830 down-regulates overactive T cells to “normalize” their activity and slow the immune system’s auto-reactive responses, reducing symptoms of autoimmune disease.3

Currently in Phase 2b clinical trials for atopic dermatitis, ISB 830 offers an entirely new mechanism of action to treat autoimmune disease and has the potential to address a range of conditions.4 The treatment may change lives, and the way autoimmune disease are treated—from now on.


research

At Ichnos Sciences, we’re working to change the therapeutic approaches of autoimmune diseases.

With a deep understanding of the body’s aberrant autoimmune response that leads to the immune system attacking healthy cells and causing inflammation, our molecule, ISB 830, is designed to block the key immune system activation factor, OX-40.3 By blocking OX-40 on the surface of T cells, ISB 830 down-regulates overactive T cells to “normalize” their activity and slow the immune system’s auto-reactive responses, reducing symptoms of autoimmune disease.3

Currently in Phase 2b clinical trials for atopic dermatitis, ISB 830 offers an entirely new mechanism of action to treat autoimmune disease and has the potential to address a range of conditions.4 The treatment may change lives, and the way autoimmune disease are treated—from now on.

Shifting from pain to progress
research

Shifting from pain to progress

For too long, pain management as a clinical area of focus has cried out for change.5 We’re committed to bringing responsible pain management medication forward.

Our goal is to develop differentiated medicines that will help individuals suffering from pain return to a better quality of life. We believe our holistic focus on diseases and patients will get us there faster.

Because the world is waiting.


research

For too long, pain management as a clinical area of focus has cried out for change.5 We’re committed to bringing responsible pain management medication forward.

Our goal is to develop differentiated medicines that will help individuals suffering from pain return to a better quality of life. We believe our holistic focus on diseases and patients will get us there faster.

Because the world is waiting.

1.

Burugu, S., Dancsok, A. R. & Nielsen, T. O. Emerging targets in cancer immunotherapy. Seminars in Cancer Biology 52, 39–52 (2018).

2.

Glenmark Pharmaceuticals S.A. Glenmark Bispecific Clinical Trials. Available here. NLM identifiers: NCT03983395, NCT02829372, NCT03309111. Accessed: 12th August 2019.

3.

Guttman-Yassky, E. et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J. Allergy Clin. Immunol. 144, 482-493.e7 (2019).

4.

Glenmark Pharmaceuticals S.A. GBR 830 Clinical Trials. Available here. NLM identifiers: NCT02683928, NCT03568162. (Accessed: 12th August 2019).

5.

Pergolizzi, J. V, Paladini, A., Varrassi, G. & Raffa, R. B. Change Pain: Ever Evolving—An Update for 2016. Pain Ther. 5, 127–133 (2016).

* Assets that were previously identified as GBR and GRC are now identified as ISB (for biologics) and ISC (for small molecules), respectively.

View Career Opportunities

United States

Switzerland

India

You are now leaving the Ichnos Sciences Inc. website.


The link you have selected is provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.


Cancel Continue

You are now leaving the Ichnos Sciences Inc. website.


The link you have selected is provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.


Cancel Continue